Moleculin Biotech (MBRX) Projected to Post Quarterly Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) is anticipated to post its Q4 2025 results before the market opens on Friday, March 20th. Analysts expect Moleculin Biotech to post earnings of ($7.77) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 23, 2026 at 4:00 PM ET.

Moleculin Biotech Trading Up 1.0%

Shares of NASDAQ MBRX opened at $2.05 on Friday. Moleculin Biotech has a 12 month low of $1.79 and a 12 month high of $33.00. The company has a 50 day simple moving average of $3.63 and a two-hundred day simple moving average of $7.50. The stock has a market cap of $4.18 million, a price-to-earnings ratio of -0.06 and a beta of 1.73.

Analyst Ratings Changes

A number of research firms recently issued reports on MBRX. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target (up from $4.00) on shares of Moleculin Biotech in a research report on Thursday, December 11th. Finally, Roth Mkm reissued a “buy” rating on shares of Moleculin Biotech in a report on Monday, December 15th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Moleculin Biotech has an average rating of “Moderate Buy” and a consensus target price of $61.00.

Institutional Investors Weigh In On Moleculin Biotech

A hedge fund recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.